A specific synbiotic-containing amino acid-based formula in dietary management of cow’s milk allergy: a randomized controlled trial
Специфическая смесь на основе аминокислот, содержащая синбиотики, для диетотерапии аллергии на белок коровьего молока: рандомизированное контролируемое исследование
2019-01-14
SCID: 54.1/tbbd5saz
Discuss with AI
Bifidobacterium breve M-16Vamino acid-based formulacow's milk allergyfecal microbiotasynbiotics
Figures from the paper
Abstract (AI)
Here we report follow-up data from a double-blind, randomized, controlled multicenter trial, which investigated fecal microbiota changes with a new amino acid-based formula (AAF) including synbiotics in infants with non-immunoglobulin E (IgE)-mediated cow’s milk allergy (CMA). Subjects were randomized to receive test product (AAF including fructo-oligosaccharides and Bifidobacterium breve M-16V) or control product (AAF) for 8 weeks, after which infants could continue study product until 26 weeks. Fecal percentages of bifidobacteria and Eubacterium rectale / Clostridium coccoides group ( ER/CC ) were assessed at 0, 8, 12, and 26 weeks. Additional endpoints included stool markers of gut immune status, clinical symptoms, and safety assessments including adverse events and medication use. The trial included 35 test subjects, 36 controls, and 51 in the healthy reference group. Study product was continued by 86% and 92% of test and control subjects between week 8–12, and by 71% and 80%, respectively until week 26. At week 26 median percentages of bifidobacteria were significantly higher in test than control [47.0% vs. 11.8% ( p < 0.001)], whereas percentages of ER/CC were significantly lower [(13.7% vs. 23.6% ( p = 0.003)]. Safety parameters were similar between groups. Interestingly use of dermatological medication and reported ear infections were lower in test versus control, p = 0.019 and 0.011, respectively. Baseline clinical symptoms and stool markers were mild (but persistent) and low, respectively. Symptoms reduced towards lowest score in both groups. Beneficial effects of this AAF including specific synbiotics on microbiota composition were observed over 26 weeks, and shown suitable for dietary management of infants with non-IgE-mediated CMA. Trial Registration NTR3979
Key Findings
1
A double-blind randomized multicenter trial evaluated an amino acid-based formula containing fructo-oligosaccharides and Bifidobacterium breve M-16V in infants with non-IgE-mediated cow’s milk allergy.
2
After 26 weeks, the synbiotic formula produced significantly higher fecal bifidobacteria than control formula (47.0% vs. 11.8%; p < 0.001).
3
At week 26, the synbiotic formula produced significantly lower Eubacterium rectale/Clostridium coccoides group percentages than control (13.7% vs. 23.6%; p = 0.003).
4
Clinical symptoms decreased toward the lowest scores in both formula groups, while overall safety parameters were similar.
5
Dermatological medication use and reported ear infections were significantly lower with the synbiotic formula than with control (p = 0.019 and p = 0.011, respectively).
6
The synbiotic-containing amino acid formula was considered suitable for dietary management of infants with non-IgE-mediated cow’s milk allergy and beneficially influenced microbiota composition over 26 weeks.
Research Object
Infants with non-IgE-mediated cow’s milk allergy receiving amino acid-based formula with or without synbiotics
Research Subject
Longitudinal effects of a synbiotic-containing amino acid-based formula on fecal microbiota composition, gut immune-status markers, clinical symptoms, and safety
Publication Details
Publication Date
2019-01-14
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest